HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
hydrochloride N- diaminomethylene- 2- methyl- 5- methylsulfonyl- 4- pyrrolobenzamide
structure in first source
Also Known As:
N-diaminomethylene-2-methyl-5-methylsulfonyl-4-pyrrolobenzamide, hydrochloride; EMD 85 131; EMD 85131
Networked:
2
relevant articles (
1
outcomes,
0
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Organic Chemicals: 133
Amides: 2428
Benzamides: 115
hydrochloride N-diaminomethylene-2-methyl-5-methylsulfonyl-4-pyrrolobenzamide: 2
Hydrocarbons: 1713
Cyclic Hydrocarbons: 97
Aromatic Hydrocarbons: 291
Benzene Derivatives: 17
Benzoates: 426
Benzamides: 115
hydrochloride N-diaminomethylene-2-methyl-5-methylsulfonyl-4-pyrrolobenzamide: 2
Carboxylic Acids: 973
Carbocyclic Acids
Benzoates: 426
Benzamides: 115
hydrochloride N-diaminomethylene-2-methyl-5-methylsulfonyl-4-pyrrolobenzamide: 2
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Azoles: 2138
Pyrroles: 369
hydrochloride N-diaminomethylene-2-methyl-5-methylsulfonyl-4-pyrrolobenzamide: 2
Experts
1.
Beier, N
: 1 article (06/2000)
2.
Gross, G J
: 1 article (06/2000)
3.
Gumina, R J
: 1 article (06/2000)
4.
Schelling, P
: 1 article (06/2000)
Related Diseases
1.
Infarction (Infarctions)
07/01/1998 - "
To address this question, the efficacy of several doses of a new selective NHE-1 isoform inhibitor (IC50 for inhibition of 22Na uptake in NHE-1 expressing mouse fibroblast cells = 10.4 +/- 1.0 nM), EMD 85131 (2-methyl-5-methylsulfonyl-1-(1-pyrrollyl)-benzoyl-guanidine), was tested in a canine infarct model in which the left anterior descending coronary artery was occluded for 60 min followed by 3 hr of reperfusion.
"
07/01/1998 - "
A new sodium/hydrogen exchange inhibitor, EMD 85131, limits infarct size in dogs when administered before or after coronary artery occlusion.
"
06/01/2000 - "
With an in vivo canine infarct model in which the left anterior descending coronary artery was occluded for 60 min and reperfused for 3 h, neither the K(ATP) channel antagonist glibenclamide nor the adenosine-receptor antagonist PD 115199 attenuated NHE-1 inhibitor-mediated reduction in infarct size expressed as a percentage of the area at risk produced by EMD 85131 (Control, 24.2 +/- 3.6%; EMD 85131, 6.4 +/- 2.3%; PD 115199 + EMD 85131, 6.6 +/- 2.4%; glibenclamide + EMD 85131, 3.5 +/- 1.2%).
"
Related Drugs and Biologics
1.
Protein Isoforms (Isoforms)
2.
Purinergic P1 Receptor Antagonists
3.
Sodium
4.
Hydrogen
5.
Glyburide (Glibenclamide)
6.
Adenosine Triphosphate (ATP)
7.
N- (2- (dimethylamino)ethyl)- N- methyl- 4- (2,3,6,7- tetrahydro- 2,6- dioxo- 1,3- dipropyl- 1H- purin- 8- yl)benzenesulfonamide